Dernières nouvelles pour Mainz Biomed (NASDAQ:MYNZ) Stock

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) narrows FY2025 GAAP EPS guidance from $5.80-$6.20 to $5.95-$6.15 vs $6.19 analyst estimate..

News

Guidance

ITT Narrows FY2025 GAAP EPS Guidance from $5.80-$6.20 to $5.95-$6.15 vs $6.19 Est

OMCL

Omnicell Sees Q3 Adj EPS $0.30-$0.37 vs $0.30 Est; Sees Sales $290.000M-$300.000M vs $284.09M Est

ITT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) raises FY2025 Adj EPS guidance from $6.10-$6.50 to $6.35-$6.55 vs $6.41 analyst estimate. Raises FY2025 sales outlook from $3.704 billion-$3.776 billion to $3.813 billion-$3.885 billion vs $3.780 billion estimate.

ITT Raises FY2025 Adj EPS Guidance from $6.10-$6.50 to $6.35-$6.55 vs $6.41 Est; Raises FY2025 Sales Guidance from $3.704B-$3.776B to $3.813B-$3.885B vs $3.780B Est

BorgWarner's Board Of Directors Authorized An Increase To Its Share Repurchase Program To $1B, Allowing Management To Repurchase BorgWarner Outstanding Shares Through 2028

Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) affirms FY2025 Adj EPS guidance from $2.05 to $2.05 vs $2.03 analyst estimate..

NCLH

Norwegian Cruise Line Affirms FY2025 Adj EPS Guidance of $2.05 vs $2.03 Est

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) raises FY2025 GAAP EPS guidance from $6.51-$6.91 to $6.73-$7.13 vs $8.31 analyst estimate..

Teleflex Raises FY2025 GAAP EPS Guidance from $6.51-$6.91 to $6.73-$7.13 vs $8.31 Est

CVS Health Lowers FY2025 GAAP EPS Guidance from $4.23-$4.43 to $3.84-$3.94 vs $4.33 Est

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.77) by 8.73 percent. This is a 14.2 percent decrease over losses of $(1.69) per share from the same period last year. The company reported quarterly sales of $12.455 million which beat the analyst consensus estimate of $9.537 million by 30.59 percent. This is a 44.57 percent increase over sales of $8.615 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

AGIO

Agios Pharmaceuticals Q2 EPS $(1.93) Misses $(1.77) Estimate, Sales $12.455M Beat $9.537M Estimate

Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.54 by 6.08 percent. This is a 410 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $633.576 million which missed the analyst consensus estimate of $814.243 million by 22.19 percent. This is a 44.95 percent increase over sales of $437.109 million the same period last year.

Cameco Q2 Adj. EPS $0.51 Misses $0.54 Estimate, Sales $633.576M Miss $814.243M Estimate

2025 Full-Year Guidance
<ul>
<li>Revised GAAP diluted EPS guidance range to $3.84 to $3.94 from $4.23 to $4.43</li>
<li>Raised Adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20</li>
<li>Raised cash flow from operations guidance to at least $7.5 billion from approximately $7.0 billion</li>
</ul>

CVS Health Raises FY2025 Adj EPS Guidance from $6.00-$6.20 to $6.30-$6.40 vs $6.13 Est

PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate of $(0.98) by 4.78 percent. This is a 90.74 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $7.47 billion which beat the analyst consensus estimate of $7.08 billion by 5.63 percent. This is a 14.43 percent decrease over sales of $8.74 billion the same period last year.

PBF Energy Q2 Adj. EPS $(1.03) Misses $(0.98) Estimate, Sales $7.47B Beat $7.08B Estimate

Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) raises FY2025 Adj EPS guidance from $3.00-$3.15 to $3.10-$3.20 vs $3.11 analyst estimate. Raises FY2025 sales outlook from $2.970 billion-$3.050 billion to $3.020 billion-$3.070 billion vs $3.017 billion estimate.

Vontier Raises FY2025 Adj EPS Guidance from $3.00-$3.15 to $3.10-$3.20 vs $3.11 Est; Raises FY2025 Sales Guidance from $2.970B-$3.050B to $3.020B-$3.070B vs $3.017B Est

CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) affirms FY2025 Adj EPS guidance from $3.54-$3.60 to $3.54-$3.60 vs $3.59 analyst estimate..

CMS Energy Affirms FY2025 Adj EPS Guidance of $3.54-$3.60 vs $3.59 Est

Omnicell Q2 Adj. EPS $0.45 Beats $0.21 Estimate, Sales $290.56M Beat $275.85M Estimate

Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) is looking for Q3 Adj EPS of $0.74-$0.78 vs $0.78 analyst estimate. sees sales of $745.000 million-$755.000 million vs $754.316 million analyst estimate.

Vontier Sees Q3 Adj EPS $0.74-$0.78 vs $0.78 Est; Sees Sales $745.000M-$755.000M vs $754.316M Est

Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) reported quarterly earnings of $0.51 per share which met the analyst consensus estimate. This is a 27.5 percent increase over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $2.517 billion which missed the analyst consensus estimate of $2.554 billion by 1.42 percent. This is a 6.13 percent increase over sales of $2.372 billion the same period last year.

Norwegian Cruise Line Q2 Adj. EPS $0.51, Inline, Sales $2.517B Miss $2.554B Estimate

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) reported quarterly earnings of $3.73 per share which beat the analyst consensus estimate of $3.36 by 11.04 percent. This is a 9.06 percent increase over earnings of $3.42 per share from the same period last year. The company reported quarterly sales of $780.889 million which beat the analyst consensus estimate of $771.477 million by 1.22 percent. This is a 4.16 percent increase over sales of $749.691 million the same period last year.

Teleflex Q2 Adj. EPS $3.73 Beats $3.36 Estimate, Sales $780.889M Beat $771.477M Estimate

Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.19 by 8.6 percent. This is a 10.53 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $366.700 million which beat the analyst consensus estimate of $360.607 million by 1.69 percent. This is a 2.95 percent increase over sales of $356.190 million the same period last year.

Utz Brands Q2 Adj. EPS $0.17 Misses $0.19 Estimate, Sales $366.700M Beat $360.607M Estimate

Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) raises FY2025 GAAP EPS guidance from $5.65-5.85 to $5.70-5.85 vs $5.84 analyst estimate..

Idacorp Raises FY2025 GAAP EPS Guidance from $5.65-5.85 to $5.70-5.85 vs $5.84 Est

CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.34 percent. This is a 7.58 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $1.838 billion which beat the analyst consensus estimate of $1.681 billion by 9.32 percent. This is a 14.37 percent increase over sales of $1.607 billion the same period last year.

CMS Energy Q2 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $1.838B Beat $1.681B Estimate

Health Care

Press Releases

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Financing

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

MYNZ

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptevo Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Genprex

GRI Bio

GT Biopharma

IN8bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mustang Bio

Palisade Bio

Polyrizon

PharmaCyte Biotech

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Tharimmune

Turnstone Biologics

VivoSim Labs

Xenetic Biosciences

Maxim Group

JonesTrading

Screenshot 2025-04-15 at 7.03.21 PM

Biotech

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2025-04-02 at 9.29.30 PM

General

Mainz BioMed&#39;s Trial To Bring Critical Early Cancer Detection One Step Closer

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Mainz Biomed

Actualités

Dernières nouvelles pour Mainz Biomed (NASDAQ:MYNZ) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL